Micropulse Laser Therapy as an Integral Part of Eye Disease Management.

Ocular diseases can significantly impact vision and quality of life through pathophysiological alterations to the structure of the eye. The management of these conditions often involves a combination of pharmaceutical interventions, surgical procedures, and laser therapy. Laser technology has revolutionized many medical fields, including ophthalmology, offering precise and targeted treatment options that solve some of the unmet needs of other therapeutic strategies. Conventional laser techniques, while effective, can generate excessive thermal energy, leading to collateral tissue damage and potential side effects. Compared to conventional laser techniques, micropulse laser therapy delivers laser energy in a pulsed manner, minimizing collateral damage while effectively treating target tissues. The present paper highlights the advantages of micropulse laser therapy over conventional laser treatments, presents the implications of applying these strategies to some of the most prevalent ocular diseases, and highlights several types and mechanisms of micropulse lasers. Although micropulse laser therapy shows great potential in the management of ocular diseases, further research is needed to optimize treatment protocols, evaluate long-term efficacy, and explore its role in combination therapies.

Exploring New Therapeutic Avenues for Ophthalmic Disorders: Glaucoma-Related Molecular Docking Evaluation and Bibliometric Analysis for Improved Management of Ocular Diseases.

Ophthalmic disorders consist of a broad spectrum of ailments that impact the structures and functions of the eye. Due to the crucial function of the retina in the vision process, the management of eye ailments is of the utmost importance, but several unmet needs have been identified in terms of the outcome measures in clinical trials, more proven minimally invasive glaucoma surgery, and a lack of comprehensive bibliometric assessments, among others. The current evaluation seeks to fulfill several of these unmet needs via a dual approach consisting of a molecular docking analysis based on the potential of ripasudil and fasudil to inhibit Rho-associated protein kinases (ROCKs), virtual screening of ligands, and pharmacokinetic predictions, emphasizing the identification of new compounds potentially active in the management of glaucoma, and a comprehensive bibliometric analysis of the most recent publications indexed in the Web of Science evaluating the management of several of the most common eye conditions. This method resulted in the finding of ligands (i.e., ZINC000000022706 with the most elevated binding potential for ROCK1 and ZINC000034800307 in the case of ROCK2) that are not presently utilized in any therapeutic regimen but may represent a future option to be successfully applied in the therapeutic scheme of glaucoma following further comprehensive testing validations. In addition, this research also analyzed multiple papers listed in the Web of Science collection of databases via the VOSviewer application to deliver, through descriptive analysis of the results, an in-depth overview of publications contributing to the present level of comprehension in therapeutic approaches to ocular diseases in terms of scientific impact, citation analyses, most productive authors, journals, and countries, as well as collaborative networks. Based on the molecular docking study's preliminary findings, the most promising candidates must be thoroughly studied to determine their efficacy and risk profiles. Bibliometric analysis may also help researchers set targets to improve ocular disease outcomes.

Subconjunctival ocular filariasis -Case report.

We are presenting the case of a patient who was clinically diagnosed with subconjunctival ocular dirofilariasis, confirmed by the parasitological examination. The treatment consisted in the surgical extraction of the parasite, a local treatment with antibiotics and steroidal anti-inflammatory mydriatic and general treatment with antihelminthic, antibiotic, analgesic, and anti-inflammatory drugs. The intraoperative and postoperative evolution of the case was favorable.

[L-carnitine decreases oxidative stress induced by experimental hypobaric hypoxia].

INTRODUCTION: It is known that exposure to severe hypobaric hypoxia induces changes of reactive oxygen species (ROS) and antioxidant systems. L-carnitine, a natural compound, has an antioxidant effect and decreases lipid peroxidation. The aim of this study was to investigate the protective effects of L-carnitine treatment on oxidative stress induced by exposure to hypobaric hypoxia. MATERIAL AND METHODS: 30 male Wistar rats were divided into 3 equal-size groups: 1st group - a control group, kept in normoxic conditions; 2nd group - rats exposed to hypobaric hypoxia in the barochamber (simulated high altitude equivalent to 5500 meters) for a 14-day placebo; 3rd group - rats exposed to hypobaric hypoxia for 14 days and treated with L-carnitine (L-carnitine, 100 mg/kg) every day. After 14 days, the serum levels of lipid peroxides expressed by the value of malondialdehyde (MDA), and the serum levels of carbonylated proteins (CP), glutathione (GSH) and donor hydrogen ability (DHA) were determined for all rats. RESULTS: The results indicated an increase in MDA and CP levels, after the exposure to hypobaric hypoxia. L-carnitine significantly decreased (p <0.05) the levels of the MDA and CP and significantly increased (p <0.05) the serum antioxidant capacity: glutathione and DHA. CONCLUSION: This study suggests that the administration of L-carnitine can be beneficial in attenuating the oxidative stress associated with exposure to high altitude.